

-1- BASIC DOC. -

C07D209/88

ation number:

0004 342
A1

Office européen des brevets

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 79100780.0

(51) Int. Cl.2: C 07 D 209/88, A 61 K 31/40

(22) Date of filing: 15.03.79

(30) Priority: 17.03.78 US 887799

(71) Applicant: E.I. du Pont de Nemours and Company,
1007 Market Street, Wilmington, Del. 19898 (US)

(43) Date of publication of application: 03.10.79
Bulletin 79/20

(72) Inventor: Fliedner, Leonard John, Jr., 109 Mineola
Avenue, Point Lookout New York New York 11569 (US)

(84) Designated Contracting States: BE CH DE FR GB IT LU
NL SE

(74) Representative: von Kreisler, Alek, Dipl.-Chem. et al,
Deichmannhaus am Hauptbahnhof, D-5000 Köln 1 (DE)

(54) Carbazoles, process for their preparation, pharmaceutical compositions containing them, and intermediates thereto.

(57) 2-Amino- and 2-(substituted amino)-tetrahydro- and
-cis-hexahydro-carbazoles, useful for alleviating depression
in mammals and intermediate compounds thereto.

EP 0 004 342 A1

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)

TITLE MODIFIED
see front page

EP 0208

1

EP-0208

TITLE


ANTIDEPRESSANT CARBAZOLES

AND INTERMEDIATES THERETOBACKGROUND OF THE INVENTION

5 This invention relates to tetrahydrocarbazoles and cis-hexahydrocarbazoles useful as antidepressant agents and intermediates thereto.

Mooradian in U.S. 3,959,309 discloses anal-
getic and psychotropic activity for compounds such as


10



15

Mooradian et al., [J. Med. Chem. 18, 640
(1975)], discloses that compounds such as


20



produce cardiostimulant effects in dogs.

Canas-Rodriguez, in U.S. 3,720,711 discloses
antidepressant activity for compounds such as

25





5
Mental illnesses include psychoses and neuroses. The symptoms requiring treatment include depression, anxiety, agitation and hallucinations. Drugs used particularly for treatment of both reactive and endogenous depressions include monoamine oxidase (MAO) inhibitors such as tranylcypromine, nialamide, phenelzine and pargyline and the non-MAO inhibiting tricyclic aromatic
15 dibenzazepines such as imipramine and dibenzocycloheptenes such as amitriptyline.

All of these drugs have side effects that limit their usefulness. The MAO inhibitors may cause tremors, insomnia, hyperhydrosis, agitation, hypermanic
20 behavior, confusion, hallucinations, convulsions, orthostatic hypertension and death. They frequently cause dizziness, vertigo, headache, inhibition of ejaculation, difficulty in urination, weakness, fatigue, dry mouth, constipation and blurred vision. Imipramine may cause
25 blurred vision, dryness of mouth, constipation, urinary retention, orthostatic hypotension, respiration depression, myocardial infarction and congestive heart failure. Similar difficulties are experienced with amitriptyline.

30 The present invention results from efforts to develop new psychotherapeutic compounds which are effective and have minimal side effects. These compounds can be more effective in treating depression than presently available drugs.

SUMMARY OF THE INVENTION

This invention relates to compounds of Formulae I and II and pharmaceutically suitable salts thereof, processes for their manufacture, compositions containing 5 specific compounds of Formulae I and II or their salts, and methods of using specific compounds of Formulae I and II or their salts to alleviate depression in mammals.



wherein

- 20 R_1 is hydrogen, methyl, ethyl, or $R-\overset{\overset{O}{\parallel}}{C}-$, where R is hydrogen, C_1-C_4 alkyl, methoxy or ethoxy;
 R_2 is hydrogen or methyl;
 R_3 is hydrogen, methyl or ethyl;
 Y_1 is hydrogen, fluorine, chlorine, bromine,
 25 hydroxy, methyl, benzyloxy or C_1-C_6 alkoxy;
 Y_2 is hydrogen or chlorine;
 with the proviso that Y_2 can be chlorine only when Y_1 is chlorine.

DETAILED DESCRIPTION OF THE INVENTION30 Compounds with Antidepressant Utility

Compounds with antidepressant utility include the compounds of Formula I; also, the compounds of Formula II (referred to as IIa) which have this utility are where:

35

4

R_1 is hydrogen, methyl, ethyl, or $R-\overset{\text{O}}{\underset{||}{C}}-$, where R is methyl or ethoxy;

R_2 is hydrogen or methyl, provided when R_1 is $R-\overset{\text{O}}{\underset{||}{C}}$ and R is methyl, then R_2 is hydrogen;

5 R_3 is hydrogen, methyl or ethyl;

Y_1 is hydrogen, fluorine, chlorine, bromine, methyl, benzyloxy or C_1-C_6 alkoxy;

Y_2 is hydrogen or chlorine;

with the proviso that Y_2 can be chlorine only when Y_1 is chlorine.

Preferred Compounds

Compounds preferred because of their high degree of antidepressant activity are those compounds of Formula I wherein

15 R_1 is hydrogen, methyl or $R-\overset{\text{O}}{\underset{||}{C}}-$, where R is C_1-C_4 alkyl, methoxy or ethoxy; or

R_2 is hydrogen; or

R_3 is hydrogen, methyl or ethyl; or

Y_1 is hydrogen, fluorine, chlorine, bromine or

20 C_1-C_4 alkoxy; or

Y_2 is hydrogen.

Also preferred are those compounds of Formula

IIa where

25 R_1 is hydrogen, methyl or $R-\overset{\text{O}}{\underset{||}{C}}-$, where R is methyl or ethoxy; or

R_2 is hydrogen; or

R_3 is hydrogen, methyl or ethyl; or

Y_1 is hydrogen, fluorine, chlorine, bromine or

C_1-C_4 alkoxy; or

30 Y_2 is hydrogen.

More preferred are those compounds of Formulae I and IIa where R_1 , R_2 , R_3 and Y_1 have the preferred definitions. Most preferred are those compounds of Formulae I and IIa where

35

R_1 is hydrogen, methyl or $R-\overset{\overset{O}{\parallel}}{C}-$, where R is C_1-C_4 alkyl, methoxy or ethoxy, except that in Formula IIa, R is limited to methyl or ethoxy;

R_2 is hydrogen;


5 R_3 is hydrogen, methyl or ethyl;

Y_1 is hydrogen or C_1-C_4 alkoxy; and


Y_2 is hydrogen.

Nomenclature

Formulae I and II encompass tetrahydro- and
10 hexahydro- derivatives of the carbazole ring system.




15 Typical examples of nomenclature for the compounds of the present invention are given as follows:




20

N-(6-fluoro-1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide.




25

2,3,4,9-Tetrahydro-N-methyl-1H-carbazol-2-amine.



30

N-(cis-1,3,4,4a,9,9a-hexahydro-9-methyl-2H-carbazol-2-yl)acetamide.




35

cis-N,N-dimethyl-2,3,4,4a,9,9a-hexahydro-1H-carbazole-2-amine.

Synthesis

Compounds of Formula I are prepared by the reduction of compounds of Formula II wherein R_1 , R_2 , R_3 , Y_1 and Y_2 are as previously defined.




10 The reduction of tetrahydrocarbazoles to hexahydrocarbazoles is well known in the prior art, e.g.,
 (a) the use of metal-acid mixtures [e.g., tin and hydrochloric acid, cf. B. Robinson, Chem. Rev. 69, 785 (1969)], (b) catalytic hydrogenation in the presence of
 15 noble metals and acidic activators [e.g., platinum in ethanolic-aqueous fluoroboric acid, cf. A. Smith, et al. Chem. Commun. 427 (1965)], (c) the use of trimethylamine-borane [cf. J. G. Berger, Synthesis, 508, (1974)],
 (d) the use of sodium borohydride- or sodium-cyanoborohydride-carboxylic acid systems [cf. G. W. Gribble et al., J. Am. Chem. Soc. 96, 7812 (1974)].

Procedure (d), that of G. W. Gribble, et al., was found to be particularly effective and convenient for the reduction. In this process the compounds of
 25 Formula II are dissolved or suspended in a convenient volume of a suitable acidic solvent such as glacial acetic acid, trifluoroacetic acid, or methanolic hydrogen chloride, followed by the addition of sodium cyanoborohydride (NaBH_3CN). NaBH_3CN as obtained from commercial
 30 sources is usually hygroscopic and although it can be added to the reaction mixture in its solid form, it is, in practice, convenient to dissolve the reagent in an inert solvent which is appreciably soluble such as methyl alcohol or ethyl alcohol and then to add the
 35 resulting solution to the reaction mixture in a controlled manner. During the addition of the NaBH_3CN

(either as a solid or in solution), it is desirable to maintain the internal temperature of the reaction mixture at between 0°C and 50°C in order to mitigate the exothermicity and effervescence which accompany said addition. The molar ratio of NaBH_3CN to compound of Formula II is between one and ten. Following the addition of the NaBH_3CN , the reaction is brought to completion by stirring the mixture at from ambient temperature to 100°C for between one and twenty-four hours.

The use of sodium borohydride (NaBH_4)-carboxylic acid systems for the alkylation of amines as described by P. Marchini, et al., [J. Org. Chem., 40, 3453 (1975)] provides an effective alternate method for the preparation of compounds of Formula I wherein R_3 is

methyl or ethyl, R_1 is $-\overset{\text{O}}{\underset{\text{||}}{\text{C}}}-\text{R}$ where R , R_2 , Y_1 and Y_2 are as previously defined. In this process, compounds of Formula I with the constituents as defined, except R_3 is hydrogen, are alkylated on the nitrogen atom at position 9 by treatment




with an excess of sodium borohydride and an excess of either formic acid or acetic acid, depending on the alkyl substituent to be introduced, i.e., where R_3 = methyl (Me) or ethyl (Et), respectively. The reaction is carried out at a temperature of from 20°C to 100°C either with or without added inert solvent for a period of from one to twenty-four hours. Suitable inert solvents include benzene and tetrahydrofuran.

With respect to the molecular plane passing through carbon atoms 2, 4a, and 9a of compounds of Formula I, the hydrogen atom at position 4a may be

spatially oriented on the same side (cis-relationship) or on the opposite side (trans-relationship) of the plane as the hydrogen atom at position 9a. The hexahydrocarbazoles of Formula I are cis-isomers, that is, the hydrogen atoms at positions 4a and 9a are spatially oriented on the same side of the molecular plane passing through carbon atoms 2, 4a and 9a.

Each of the cis-compounds of Formula I exist in two diastereoisomeric forms by virtue of the asymmetric carbon atom at position 2, and the invention includes the compounds as the separate diastereoisomers, as well as mixtures thereof, as produced by the above methods. The diastereoisomeric forms in turn can be resolved into optically-active dextrorotatory (+) and levorotatory (-) enantiomers by methods known to the art. All of these optical isomers are included within the scope of the invention since they have utility in alleviating depression in mammals.

The compounds of Formula II which serve as useful intermediates for the synthesis of compounds of Formula I and which also, in many cases, possess antidepressant activity themselves, are prepared by the process known in the art as the Fischer Indole Synthesis. Thus, they are obtained by reacting an appropriate phenylhydrazine of Formula III, wherein R_3 , Y_1 and Y_2 are as defined in Formula I, with a cyclohexanone derivative of Formula IV, wherein R_1 and R_2 are as defined in Formula I, in an acidic medium, at elevated temperatures, for from about 1/2 to 24 hours. The acid cyclizing agent can be an inorganic hydrohalide such as hydrochloric acid or hydrobromic acid, or a mineral acid such as phosphoric acid or sulfuric acid, an organic acid such as acetic acid or methanesulfonic acid, or a Lewis acid such as boron trifluoride or zinc chloride. The acidic agent should be present in at least one mole




10

in excess per mole of the phenylhydrazine. The reaction is conveniently carried out by heating the reactants in acetic acid at from 80°C to 120°C or in ethanolic hydrogen chloride at reflux temperature. The reaction proceeds via the corresponding phenylhydrazone precursor (V) which can be isolated, if desired, by using only a catalytic amount of acid. Subsequent treatment of the phenylhydrazone precursor (V) under acidic conditions, as described above, will effect cyclization to the corresponding tetrahydrocarbazoles of Formula II.

The starting materials III and IV are either commercially available, known to the art, or readily preparable by conventional means.


All of the tetrahydrocarbazoles of Formula II need not be prepared via the Fischer Indole reaction. Instead, interconversions among these compounds are possible in which one tetrahydrocarbazole of Formula II serves as a precursor for another tetrahydrocarbazole of Formula II. Such transformations are effected by conventional means and include the following:

1) Dealkylation of phenolic ethers of Formula IX, wherein R , R_2 and R_3 are as defined in Formula II, and R_4 is a methyl or benzyl group, may be carried out by means of Lewis acids under appropriate conditions




[cf. E. Haslam, "Protective Groups in Organic Chemistry", J.F.W. McOmie, Ed., Plenum Press, New York, New York, 1973, pp. 164-167]. Alternatively, hydrogenolytic conditions may be effectively employed in cleaving benzyl
 10 phenolic ethers of Formula IX (i.e., $R_4 = C_6H_5CH_2$) [cf., Idem., *ibid.*, p. 168].

2) The phenolic tetrahydrocarbazoles of Formula X, wherein R, R_2 and R_3 are as defined in Formula II, may, in turn, be O-alkylated by reaction with
 15 an alkyl halide or alkyl sulfate or alkyl sulfonate, in the presence of a base and a suitable inert solvent [cf. Idem., *ibid.*, p. 149]. The resulting




alkoxy tetrahydrocarbazoles of Formula XI, wherein R, R_2 and R_3 are as defined in Formula II, are isolated by conventional techniques.

25 3), Hydrolysis of compounds of Formula XII, wherein R, R_2 , R_3 , Y_1 and Y_2 are as defined in Formula II, with standard acidic or basic reagents such as aqueous hydrochloric acid or aqueous-alcoholic sodium




hydroxide at reflux temperature provides the amino tetrahydrocarbazoles of Formula XIII wherein R_2 , R_3 ,
 35 Y_1 and Y_2 are as defined in Formula II [cf., J. W. Barton, *ibid.*, pp. 46-50].

4) Acyl and urethane-type tetrahydrocarbazoles of Formula XIII, wherein R , R_2 , R_3 , Y_1 and Y_2 are as defined previously, are obtained by reacting a compound of Formula XII, wherein R_2 , R_3 , Y_1 and Y_2 are as defined previously, with an acylating agent [cf., Idem., ibid., pp. 46-50]. In those cases where acidic by-




products occur, such as hydrogen chloride, the acylation reaction can be conducted in the presence of a standard basic reagent such as sodium hydrogen carbonate or triethylamine. The basic reagents neutralize the acidic by-products which otherwise may have a deleterious effect on the course of the reaction. Suitable acylating agents include formamide, acetyl chloride, acetic anhydride, methyl or ethyl chloroformate, propanoyl chloride, butanoyl chloride, and pentanoyl chloride. Suitable inert solvents for carrying out the acylation reaction include benzene, ether, chloroform, or methylene chloride, or a mixture of one of these solvents with water to produce a 2-phase system.

5) Reduction of amido tetrahydrocarbazoles of Formula XIV, wherein R_2 , R_3 , Y_1 and Y_2 are defined as in Formula II and R_5 is selected from the group consisting of hydrogen, methyl, OCH_3 , or OC_2H_5 , is effected by adding the substrate either to a solution or suspension of lithium aluminum hydride (LAH) in anhydrous ethyl ether or anhydrous tetrahydrofuran (THF) or mixtures thereof or to a solution of sodium bis(2-methoxyethoxy) aluminum hydride in benzene and refluxing the resulting solutions for a period of from one to twenty-four hours. Conventional work-up procedures yield the amino tetrahydrocarbazoles of Formula XV, wherein R_2 , R_3 , Y_1 and Y_2 are as defined in Formula II and R_6 is selected from methyl or ethyl.



6) Compounds of Formula XVI wherein R and R₂ are defined as in Formula II, and W₁ is a hydrogen, a fluorine, a chlorine, a bromine atom, or a methyl, a



benzyloxy, or a C₁-C₆ alkoxy group and W₂ is a hydrogen
 15 or chlorine atom with the proviso that W₂ can be chlorine only when W₁ is chlorine, may be alkylated at the N⁹-position to yield compounds of Formula XVII, wherein R and R₂ are as defined in Formula II, W₁ and W₂ are defined as in Formula XVI and R₃ is methyl or ethyl.

20 The literature [cf. H. Heaney *et al.*, J. Chem. Soc. Perkin 1, 499 (1973) and references therein] teaches a number of methods for obtaining N-alkyl-indoles and N-alkyl-pyrroles from the corresponding unalkylated compounds in satisfactory yields.

25 Generally, the alkylation process involves reaction of the unalkylated substrate with a basic reagent sufficiently strong to form an anion at the nitrogen atom. Nucleophilic attack of this anion on the subsequently added alkylating agent then completes the
 30 reaction.

As applied to the tetrahydrocarbazoles of Formula XVI, the procedure of H. Heaney, *et al.*, (*loc. cit.*) was found to be particularly effective for obtaining N⁹-alkylated tetrahydrocarbazoles of Formula
 35 XVII. Thus, mixing of a compound of Formula XVI with a solution of potassium hydroxide in dimethyl sulfoxide (DMSO) formed the N⁹-anion of the compound of Formula

XVI which on subsequent treatment with methyl iodide or ethyl iodide formed the desired products of Formula XVII wherein R_3 is methyl or ethyl, respectively.

The compounds of Formula II exist in dextro-
5 rotatory [(+)-] and levorotatory [(-)-] optically active isomeric forms, by virtue of the asymmetric carbon atom at position 2 and the invention includes compounds in the separated [(+)-] and [(-)-] forms, as well as the racemic [(±)-] mixtures produced by the above methods.

10 Compounds of Formulae I and II can be converted to acid addition salts. The appropriate compounds of Formulae I and II form pharmaceutically acceptable addition salts with, for example, both pharmaceutically acceptable organic and inorganic acids, such as acetic acid, citric acid, maleic acid, methanesulfonic
15 acid, succinic acid, tartaric acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid and the like. Nonpharmaceutically acceptable acid addition salts of appropriate compounds of Formulae I and II may be useful in the purification and isolation procedures and can be converted
20 into pharmaceutically acceptable acid addition salts via conventional metathetic reactions whereby the nonpharmaceutically acceptable anion is replaced by a pharmaceutically acceptable anion; or alternatively, by
25 neutralizing the nonpharmaceutically acceptable acid addition salt and then reacting the so-obtained free base with a reagent yielding a pharmaceutically acceptable acid addition salt.

Where the compounds of Formulae I and II contain one basic center, mono addition salts can be obtained by general procedures known to the art. Where
30 the compounds of Formula I contain two basic centers, mono- or di-addition salts can be obtained by general procedures known to the art depending on the relative basicity of such centers and the relative quantities of
35 the reactants and reaction conditions employed in preparing such salts.

Dosage Forms

The antidepressant agents of this invention can be administered as treatment for psychiatric depressions of the reactive and endogenous types by any means that produces contact of the active agent with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals; either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will, of course, vary depending upon known factors such as pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health and weight of the recipient; nature and extent of the symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.

The compounds of this invention will have a therapeutic dose range in man from 0.1 to 50 mg/kg/day; some of the more preferred compounds will have a dose range from 0.5 to 10 mg/kg/day and the most preferred dose range will be from 1 to 5 mg/kg/day.

Dosage forms (compositions) suitable for internal administration contain from about 2.5 milligrams to about 250 milligrams of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.01-90% by weight based on the total weight of the composition.

The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixers, syrups, and suspensions; it can also be administered

parenterally, in sterile liquid dosage forms; or rectally in the form of suppositories.

Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration contain preferably a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid either alone or combined are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA (ethylenediaminetetraacetic acid). In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suppositories contain the active ingredient in a suitable oleaginous or water-soluble base. The oleaginous class includes cocoa butter and fats with similar properties; the water-soluble class includes polyethylene glycols.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, E. W. Martin, a standard reference text in this field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules

Capsules can be prepared by filling standard two-piece hard gelatin capsules with the following mixture using conventional encapsulating equipment:

Active Ingredient	37.5 mg
Lactose	150 mg
Talc	15 mg
Magnesium stearate	7.5 mg

15 Capsules

A mixture of active drug in soy bean oil is prepared and injected by means of a positive displacement pump in gelatin to form soft gelatin capsules containing 37.5 mg of the active ingredient. The capsules are washed in petroleum ether and dried.

Tablets

Tablets are prepared by conventional procedures so that each unit will contain:

Active ingredient	37.5 mg
25 Spray dried lactose	200 mg
Polyvinyl pyrrolidone	2 mg
Microcrystalline cellulose	30 mg
Magnesium stearate	4 mg

Parenteral

30 A parenteral composition suitable for intramuscular administration is prepared so that each ml contains:

Active ingredient	37.5 mg
Polysorbate 80	1 mg
35 Sodium chloride	0.9 %
Methylparaben	1 mg
Propylparaben	0.1 mg
Water for Injection Q.S.	1.0 ml

Suspension

An aqueous suspension is prepared for oral administration so that each 5 mls contain:

	Active ingredient	37.5 mg
5	Methylcellulose	5 mg
	Carboxy methyl cellulose	5 %
	Syrup	30 %
	Sorbitol	15 %
	Sodium Saccharin	2 mg
10	Butterscotch flavor	0.2 %
	Sodium Benzoate	5 mg
	Water Q.S.	5 ml

Use

A standard procedure for detecting and comparing the antidepressant activity of compounds in this series for which there is good correlation with human efficacy is the prevention of tetrabenazine-induced sedation and depression in mice. [Everett, "The Dopa Response Potentiation Test and Its Use in Screening for Antidepressant Drugs", pp. 164-167 in "Antidepressant Drugs" (Proceedings of the First International Symposium), S. Garattini and M.N.G. Dukes, eds., 1967].

Groups of 10 Carworth CF₁S female mice, 18-21 g each, were fasted 1.5 hours and were intubated with antagonist compounds at oral doses of 0, 5, 25 and 125 mg/kg or 0, 1, 3, 9, 27, and 81 mg/kg in 0.20 ml of 1% Methocel (methylcellulose). The mice were challenged 30 minutes later with tetrabenazine (as the methane-sulfonate), 32 mg/kg intraperitoneally (dissolved in 0.20 ml 0.05M KCl at pH 2.0). One hour after antagonist (30 minutes after tetrabenazine), the mice were examined for signs of exploratory activity and ptosis (eyelid closure). Normal exploratory activity (relief from sedation) was recorded when a mouse lifted by the tail from a group of 10 in a testing box and placed on a stainless steel testing box lid (12.5" x

8" with 0.33" mesh) either turned its head horizontally 30° in both directions or moved to the edge of the screen within 10 seconds after being placed on the screen. Relief from ptosis was recorded when exactly two seconds after placing the mouse facing the observer, lid closure was less than 50% in both eyes.

For comparison, the marketed antidepressant amitriptylene was also tested and an ED₅₀ (effective dose in 50% of the cases) was determined. The lower the ED₅₀, the better the antidepressant. Results for compounds of this invention are tabulated in Table IV.

The following examples will more fully illustrate the preparation of the compositions of this invention. All temperatures in the examples are given in degrees Centigrade.

Example 1 (Table 1)

N-(cis-1,3,4,4a,9,9a-hexahydro-2H-carbazol-2-yl)acetamide hydrochloride (Compound 1a)

A solution of 5.70 g (0.025 mol) of N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide in 140 ml of glacial HOAc was stirred at room temperature, and, during the course of 5-10 minutes, a solution of 1.57 g (0.025 mol) of NaBH₃CN in 15 ml of MeOH was added dropwise. The reaction was mildly exothermic with gentle effervescence. After stirring overnight (ca. 16 hr.) at room temperature, the glacial HOAc was evaporated and the residue mixed with 150 ml of H₂O. Conc. HCl was added dropwise (pH 1-2), and, after stirring for 0.5-1 hr., any insolubles were removed by filtration. The clear, colorless filtrate was made basic with excess 50% NaOH, and the product was extracted with CHCl₃. The extracts were washed with H₂O, dried, evaporated, and the residue recrystallized from i-PrOH to give 3.64 g (70% yield) of white solid, m.p. 190-191°.

A solution of the free base in methanol was treated with an excess of hydrogen chloride. Addition

of anhydrous ether precipitated the title compound, which, after cooling, was filtered and recrystallized, m.p. 245-247°.

In an analogous manner, utilizing the procedure of Example 1, the compounds in Table 1 were prepared. In the preparation (0.025 mole scale) of 1 g, the glacial HOAc was evaporated and the residue treated with 60 ml of H₂O. On addition of concentrated HCl to pH 1-2, the hydrochloride salt precipitated directly from the initially clear solution and was isolated by filtration. The ten-fold molar amount of NaBH₃CN used for the preparation 1x (Table 1) was divided into two equal portions and added 7 hr apart. Stirring was then continued overnight at room temperature.

The compounds described in Table I were characterized and tested for biological activity either as the free bases or their hydrochloride salts (see Formula Column).

Example 2 (Table 1)

N-(cis-9-ethyl-1,3,4,4a,9,9a-hexahydro-2H-carbazol-2-yl)acetamide (Compound 1y)

A solution of 9.0 g (0.15 mol) of glacial acetic acid in 75 ml of THF was treated in portions with 1.89 g (0.05 mol) of NaBH₄, the temperature being kept at 20°C. When the evolution of H₂ had ceased, (ca. 3 hr), 2.30 g (0.01 mol) of N-(cis-1,3,4,4a,9,9a-hexahydro-2H-carbazol-2-yl)acetamide was added and the resulting solution was refluxed for 3 hr. After cooling, the THF was evaporated in vacuo and the residue was dissolved in CHCl₃. The CHCl₃ solution was washed with 1N aq NaOH and then dried over anhydrous K₂CO₃. Filtration followed by evaporation of the CHCl₃ left a white solid residue which after recrystallization from ethyl acetate-cyclohexane yielded 2.3 g of the title compound, mp 150-151°.

By substituting formic acid for acetic acid and otherwise utilizing the procedure of Example 2, N-(cis-1,3,4,4a,9,9a-hexahydro-9-methyl-2H-carbazol-2-yl)acetamide (Compound 1c, Table I) can be prepared from
5 N-(cis-1,3,4,4a,9,9a-hexahydro-2H-carbazol-2-yl)acetamide.

Example 3 (Table II)

N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide
(Compound 2a)

10 A stirred solution of 140.9 g (0.909 mol) of N-(3-oxocyclohexyl)acetamide in 900 ml of glacial HOAc was heated at 85-95°C while 98.2 g (0.909 mol) of phenylhydrazine was added dropwise during 1 hr. After an additional 3 hr at 95±5°, the hot solution was poured
15 into 5 l of H₂O. When the initially formed gum had solidified, the product was filtered, washed with 2.5 l of H₂O, then 2 l of Et₂O to give 167.6 g (81%) of a grey solid, mp 203-206°. Recrystallization was best effected by dissolving the crude solid in boiling Me₂CO
20 (1 g/25 ml) and boiling down to 1 g/10 ml. The resulting yellow solid (133.5 g, mp 208-209°) was recrystallized again from Me₂CO to yield 111.8 g of white solid, mp 208-209°. To remove Me₂CO occluded by the crystalline solid, the product was further recrystallized from
25 EtOH, 86% recovery of the white solid, mp 208-209°.

Example 4 (Table II)

N-(6-fluoro-1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide (Compound 2b)

A mixture of 0.05 mol of 4-fluorophenylhydrazine hydrochloride and 0.05 mol of N-(3-oxocyclohexyl)acetamide in 75 ml of glacial HOAc was stirred and heated on the steam bath. At 80-90° an exothermic reaction occurred and the source of the heat was removed until the temperature had fallen to 85°. After an additional 4-5 hr at 85-90°, the warm mixture was poured
35 into H₂O and the gummy insolubles triturated until solid. The filtered solid was washed thoroughly with H₂O and

then with Et₂O until the washings were essentially colorless. The crude product was recrystallized from ethanol to give the title compound, mp 209-210°.

By substituting 4-chlorophenylhydrazine hydrochloride, 2-fluorophenylhydrazine hydrochloride, or 3,5-dichlorophenylhydrazine hydrochloride for 4-fluorophenylhydrazine hydrochloride and otherwise utilizing the procedure of Example 4, compounds 2c, 2e and 2f (Table II), respectively, were prepared.

10 Example 5 (Table II)

N-(6-bromo-1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide (Compound 2d)

A solution of 0.05 mol of N-(3-oxocyclohexyl)-acetamide in 100 ml of glacial HOAc was stirred and 15 heated at 80°C while adding during 15-30 minutes a warm solution of 0.05 mol of 4-bromophenylhydrazine hydrochloride in 300 ml of glacial HOAc. After an additional 3 hr at 85°, most of the HOAc was evaporated. The residue was triturated with H₂O, until solid, the resulting solid 20 was filtered, and recrystallized from ethanol to give the title compound, mp 210-211°.

By substituting 4-methylphenylhydrazine hydrochloride for 4-bromophenylhydrazine hydrochloride and otherwise utilizing the procedure of Example 5, compound 25 2g (Table II) was prepared.

Example 6 (Table II)

N-(1,3,4,9-tetrahydro-6-methoxy-2H-carbazol-2-yl)acetamide (Compound 2h)

A mixture of 0.05 mol of N-(3-oxocyclohexyl)-30 acetamide, 0.05 mol of anhydrous NaOAc, 0.05 mol of 4-methoxyphenylhydrazine hydrochloride, and 155 ml of glacial HOAc was stirred for 1 hr at room temperature and then refluxed for 1 hr. The cooled reaction mixture was poured into H₂O and the product triturated 35 until solid. Filtration, drying and recrystallization from ethanol gave the title compound, mp 191-193°.

Example 7 (Table II)

N-(1,3,4,9-tetrahydro-7-methoxy-2H-carbazol-2-yl)acetamide (Compound 2i)

A mixture of 0.05 mol of N-(3-oxocyclohexyl)-acetamide and 0.05 mol of 3-methoxyphenylhydrazine hydrochloride in 50 ml of glacial HOAc was stirred for 2 hr at room temperature and then refluxed for 2 hr. The cooled reaction mixture was poured into H₂O and the product triturated until solid. Filtration, drying and recrystallization from ethanol gave the title compound, mp 192-193°.

Example 8 (Table II)

N-(7-n-butyloxy-1,3,4,9-tetrahydro-2H-carbazol-2-yl)-acetamide (Compound 2j)

A mixture of 0.2 mol of 3-n-butoxyphenylhydrazine, 0.2 mol of N-(3-oxocyclohexyl)acetamide, and 350 ml of glacial HOAc was stirred at room temperature for 3 hr and then refluxed for 2 hr. After pouring into 2.5 l of H₂O and stirring overnight, the insoluble material had partly crystallized. The crystalline material was filtered, washed with H₂O, and dried (23 g, Fraction A). The remaining insoluble semi-solid was taken up in EtOAc, washed with H₂O, dried and evaporated. The dark residue was triturated with Et₂O and filtered (6.7 g, mp 181-183°, Fraction B). Additional product was extracted from Fraction A by stirring with two 4 l. portions of Et₂O. The combined extracts were evaporated and the resulting residue combined with Fraction B and recrystallized twice from Me₂CO to yield 10.2 g of the title compound, mp 182-184°.

Example 9 (Table II)

N-(1,3,4,9-tetrahydro-7-hydroxy-2H-carbazol-2-yl)acetamide (Compound 2k)

A solution of 25.8 g (0.1 mol) of N-(1,3,4,9-tetrahydro-7-methoxy-2H-carbazol-2-yl)acetamide in 2 l.

of CH_2Cl_2 was stirred at -50 to -60°C under N_2 while adding 101 g (0.4 mol) of BBr_3 dropwise during 15-30 min. Stirring was continued for 30 min at -55°C and then 3 hr at room temperature. After cooling to -40°C , 600 ml of 5 MeOH was cautiously added dropwise during 45 min. The reaction mixture was allowed to warm to room temperature (ca. 1 hr) and then evaporated. The residue was dissolved in one l of 1N KOH, filtered from insolubles, and the cold filtrate was acidified (pH 3) with conc. 10 HCl. The precipitate was filtered, washed with H_2O and recrystallized from *i*-PrOH to give the title compound, mp $245-246^\circ$.

Example 10 (Table II)

N-(7-ethoxy-1,3,4,9-tetrahydro-2H-carbazol-2-yl)acet-
15 amide (Compound 2L)

A mixture of 0.02 mol of N-(1,3,4,9-tetrahydro-7-hydroxy-2H-carbazol-2-yl)acetamide, 0.022 mol of ethyl iodide, 0.022 mol of anhydrous K_2CO_3 , and 50 ml of Me_2CO was stirred and refluxed for 48 hr. Sufficient 20 CHCl_3 and H_2O were added to the cooled reaction mixture to give two clear layers. The CHCl_3 layer was washed with 1N NaOH, H_2O , dried, evaporated, and the resulting solid residue was recrystallized from *i*-PrOH to give the title compound, mp $184-186^\circ$.

25 By substituting *n*-propyl iodide, *n*-pentyl bromide, *n*-hexyl bromide or benzyl bromide for ethyl iodide and otherwise utilizing the procedure of Example 10, compounds 2m, 2n, 2o, and 2p (Table II), respectively, were prepared.

30 Example 11 (Table III)

2,3,4,9-Tetrahydro-1H-carbazol-2-amine hydrochloride
(Compound 3a)

A mixture of 139.3 g (0.611 mol) of N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide, 402.6 g 35 of powdered KOH, and 2 l of *n*-BuOH was stirred and refluxed under N_2 for 16 hr. The reaction mixture was

cooled to room temperature, diluted with 2.4 l of H_2O , and stirred for 1 hr. The upper organic layer was separated and evaporated while the aqueous phase was extracted with $CHCl_3$ (3x750 ml). The extracts were combined with the solid evaporation residue and the resulting solution washed with H_2O (3x750 ml) and dried. The granular solid remaining after evaporation of the $CHCl_3$ was triturated with 750 ml of Et_2O . The bulk of the product was allowed to settle and the Et_2O phase, which contained a small amount of amorphous insolubles, was decanted. This process was repeated with one-half the quantity of Et_2O . Finally, the product was collected by filtration and dried to give 99.1 g of a light cream-tan solid, mp 151-153°.

A solution of free base in methanol was treated with an excess of hydrogen chloride. Addition of anhydrous ether precipitated the title compound, which, after cooling, was filtered and recrystallized, mp ca. 290° dec.

20

Example 12 (Table III)

N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)formamide
(Compound 3b)

A mixture of 8.90 g (0.048 mol) of 2,3,4,9-tetrahydro-1H-carbazol-2-amine and 65 ml of dry formamide was stirred and heated under N_2 for 5 hr at 95-100°C. The cooled reaction mixture was poured into H_2O , and the precipitated gum extracted with $CHCl_3$. The combined extracts were washed with 0.1N HCl, 5% aqueous $NaHCO_3$, and H_2O , and dried. Et_2O -trituration of the residue remaining after evaporation of the $CHCl_3$ gave a tan solid, 8.58 g, mp 123-126°. For analysis, it was necessary to dry the recrystallized (EtOH) sample at 120° (P_2O_5 , 0.02 mm, 20 hr), mp 169-171°.

35

Example 13 (Table III)

N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)propanamide
(Compound 3c)

A solution of 0.05 mol of 2,3,4,9-tetrahydro-
5 1H-carbazol-2-amine in 450 ml of CHCl_3 and 185 ml of
saturated aqueous NaHCO_3 was stirred vigorously at room
temperature and treated dropwise during 30 min with a
solution of 0.15 mol of propanoyl chloride in an equal
volume of CHCl_3 . After stirring vigorously for 5 hr,
10 the CHCl_3 layer was separated, washed in succession
with 10% aqueous K_2CO_3 , H_2O , 0.1N hydrochloric acid,
 H_2O , and dried over anhydrous Na_2SO_4 . The residue re-
maining after evaporation of the CHCl_3 was recrystal-
lized from ethyl acetate to give the title compound,
15 mp 169-170°.

By substituting pentanoyl chloride, ethyl
chloroformate, or methyl chloroformate for propanoyl
chloride and otherwise utilizing the procedure of
Example 13, compounds 3d, 3e, and 3f (Table III), re-
20 spectively, were prepared.

Example 14 (Table III)

Methyl(1,3,4,9-tetrahydro-2H-carbazol-2-yl)carbamic
acid, ethyl ester (Compound 3g)

A solution of 0.05 mol of 2,3,4,9-tetrahydro-
25 N-methyl-1H-carbazol-2-amine in 450 ml of CH_2Cl_2 and
185 ml of saturated aqueous NaHCO_3 was stirred vigor-
ously at room temperature and treated dropwise during
30 min with a solution of 0.15 mol of ethyl chloroform-
ate in an equal volume of CH_2Cl_2 . After stirring
30 vigorously for 5 hr, the CH_2Cl_2 layer was separated,
washed in succession with 10% aqueous K_2CO_3 , H_2O , 0.1N
hydrochloric acid, H_2O , and dried over anhydrous Na_2SO_4 .
The residue remaining after evaporation of the CH_2Cl_2
was recrystallized from ethanol to give the title com-
35 pound, mp 167-168°.

Example 15 (Table III)

N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)-N-methylacetamide (Compound 3h)

A mixture of 10.0 g (0.05 mol) of 2,3,4,9-tetrahydro-N-methyl-1H-carbazol-2-amine and 70 ml of acetic anhydride was heated at reflux until complete solution occurred (2-3 min). After standing overnight at room temperature and further cooling at 0°, the precipitated solid was filtered, washed first with small portions of cold acetic anhydride and then thoroughly with anhydrous ether. The crude product was recrystallized from ethanol to give the title compound, mp 215-216°.

Example 16 (Table III)

15 N-ethyl-2,3,4,9-tetrahydro-1H-carbazol-2-amine hydrochloride (Compound 3i)

A solution of 22.8 g (0.1 mol) of N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide in 500 ml of anhydrous THF was added dropwise during 1 hr to a stirred suspension of 18.95 g (0.5 mol) of LiAlH_4 in 400 ml of anhydrous THF. The reaction was carried out in a nitrogen atmosphere. After refluxing for 36 hr, the cold reaction mixture was carefully decomposed with aqueous NaOH. The inorganic salts which precipitated were filtered, washed with THF, and the combined filtrate and washings were evaporated in vacuo to dryness. The residue was recrystallized twice from isopropanol to give the free base of the title compound, mp 170-172°.

A warm solution of the free base in methanol was treated with excess 10% methanolic hydrogen chloride. A precipitate readily formed, which, after cooling, was filtered and recrystallized to yield the title compound, mp 263-264°.

Example 17 (Table III)

2,3,4,9-Tetrahydro-N-methyl-1H-carbazol-2-amine hydrochloride (Compound 3j)

A solution of 25.8 g (0.1 mol) of (1,3,4,9-tetrahydro-2H-carbazol-2-yl)carbamic acid, ethyl ester in 150 ml of anhydrous THF was added dropwise during 1 hr to a stirred suspension of 15.2 g (0.4 mol) of LiAlH_4 in a mixture of 375 ml of anhydrous ether and 375 ml of anhydrous THF. The reaction was carried out in a nitrogen atmosphere. After refluxing for 16 hr, the cold reaction mixture was carefully decomposed with aqueous NaOH. The inorganic salts which precipitated were filtered, washed with THF, and the combined filtrate and washings were evaporated in vacuo to dryness. The residue was recrystallized twice from isopropanol to give the free base of the title compound, mp 139-140°.

A warm solution of the free base in ethanol was treated with excess 10% ethanolic hydrogen chloride. A precipitate readily formed which, after cooling, was filtered and recrystallized to yield the title compound, mp 252-253°.

By substituting methyl(1,3,4,9-tetrahydro-2H-carbazol-2-yl)carbamic acid, ethyl ester for (1,3,4,9-tetrahydro-2H-carbazol-2-yl)carbamic acid, ethyl ester and otherwise utilizing the procedure of Example 17, compound 3k (Table III) was prepared.

Example 18 (Table III)


N-(1,3,4,9-tetrahydro-9-methyl-2H-carbazol-2-yl)acetamide (Compound 3L)

A mixture of 0.1 mol of N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide, 0.15 mol of powdered KOH, and 75 ml of DMSO was stirred under nitrogen for 2 hr at room temperature. Methyl iodide (0.15 mol) was added on one portion, and, after brief cooling to moderate the exothermic reaction, the mixture was stirred

at room temperature for 2 hr. The precipitate obtained by pouring the reaction mixture into excess water was filtered, washed with water, and recrystallized from ethyl acetate to give the title compound, mp 171-172°.

5

Table I



10

No.	<u>Y₁</u>	<u>Y₂</u>	<u>R₁</u>	<u>R₂</u>	<u>R₃</u>	Example 1 Mol Ratio ^a
1a	H	H	COMe	H	H	1
1b	6-F	H	COMe	H	H	2
1c	6-Cl	H	COMe	H	H	1.5
1d	6-Br	H	COMe	H	H	1
1e	6-Me	H	COMe	H	H	1
1f	6-MeO	H	COMe	H	H	1
1g	7-HO	H	COMe	H	H	1
1h	7-MeO	H	COMe	H	H	1
1i	7-EtO	H	COMe	H	H	1
1j	7-n-PrO	H	COMe	H	H	1
1k	7-n-BuO	H	COMe	H	H	1
1L	7-n-PentO	H	COMe	H	H	1

20

25

	<u>Recrystn Solvent</u>	<u>Mp, °C</u>	<u>Formula</u>
1a	EtOH	245-247	C ₁₄ H ₁₈ N ₂ O·HCl
1b	i-PrOH	242-244	C ₁₄ H ₁₇ FN ₂ O·HCl
1c	MeOH	253-254	C ₁₄ H ₁₇ ClN ₂ O·HCl
1d	95% EtOH	243-244	C ₁₄ H ₁₇ BrN ₂ O·HCl
1e	EtOH	232-233	C ₁₅ H ₂₀ N ₂ O·HCl
1f	95% EtOH	240-241	C ₁₅ H ₂₀ N ₂ O ₂ ·HCl
1g	EtOH-H ₂ O	284-285	C ₁₄ H ₁₈ N ₂ O ₂ ·HCl
1h	H ₂ O	253-254	C ₁₅ H ₂₀ N ₂ O ₂ ·HCl
1i	i-PrOH	196-198	C ₁₆ H ₂₂ N ₂ O ₂
1j	i-PrOH	190-192	C ₁₇ H ₂₄ N ₂ O ₂
1K	i-PrOH	174-176	C ₁₈ H ₂₆ N ₂ O ₂
1L	EtOH	190-191	C ₁₉ H ₂₈ N ₂ O ₂

30


35

Table I (continued)

No.	<u>Y₁</u>	<u>Y₂</u>	<u>R₁</u>	<u>R₂</u>	<u>R₃</u>	Example 1
						Mol Ratio ^a
5	lm	7- <u>n</u> -HexO	COMe	H	H	1
	ln	7-PhCH ₂ O	COMe	H	H	1
	lo	H	COMe	H	Me	1
	lp	H	CHO	H	H	1.1
	lq	H	COEt	H	H	1.5
10	lr	H	COBu- <u>n</u>	H	H	1.5
	ls	H	CO ₂ Et	H	H	1.5
	lt	H	CO ₂ Me	H	H	1.5
	lu	H	H	H	H	2
	lv	H	Me	H	H	5
15	lw	H	Et	H	H	5
	lx	H	Me	Me	H	10
	ly	H	COMe	H	Et	-
		Recrystn	Mp, °C	Formula		
		Solvent				
20	lm	EtOH	197-199	C ₂₀ H ₃₀ N ₂ O ₂		
	ln	<u>i</u> -PrOH	183-184	C ₂₁ H ₂₄ N ₂ O ₂		
	lo	<u>i</u> -PrOH	190-191	C ₁₅ H ₂₀ N ₂ O		
	lp	MeOH	210-212	C ₁₃ H ₁₆ N ₂ O·HCl		
25	lq	EtOH	235-236	C ₁₅ H ₂₀ N ₂ O·HCl		
	lr	<u>i</u> -PrOH	184-185	C ₁₇ H ₂₄ N ₂ O		
	ls	EtOH-Et ₂ O	147-149	C ₁₅ H ₂₀ N ₂ O ₂ ·HCl		
	lt	MeOH-Et ₂ O	204-205	C ₁₄ H ₁₈ N ₂ O ₂ ·HCl		
30	lu	MeOH	304-306	C ₁₂ H ₁₆ N ₂ ·2HCl		
	lv	MeOH	275-277	C ₁₃ H ₁₈ N ₂ ·2HCl		
	lw	MeOH	273-275	C ₁₄ H ₂₀ N ₂ ·2HCl		
	lx	MeOH-Et ₂ O	243-245	C ₁₄ H ₂₀ N ₂ ·2HCl		
35	ly	EtOAc-C ₆ H ₁₂	150-151	C ₁₆ H ₂₂ N ₂ O		

a - mol(s) NaBH₃CN/mol substrate

Table II




10

No.	<u>Y₁</u>	<u>Y₂</u>	Example	Recrystn Solvent	Mp, °C	Formula
2a	H	H	3	Me ₂ CO	208-209	C ₁₄ H ₁₆ N ₂ O
2b	6-F	H	4	EtOH	209-210	C ₁₄ H ₁₅ FN ₂ O
2c	6-Cl	H	4	Me ₂ CO-CHCl ₃	207-208	C ₁₄ H ₁₅ ClN ₂ O
2d	6-Br	H	5	EtOH	210-211	C ₁₄ H ₁₅ BrN ₂ O
2e	8-F	H	4	EtOAc	209-212	C ₁₄ H ₁₅ FN ₂ O
2f	5-Cl	7-Cl	4	EtOH	232-234	C ₁₄ H ₁₄ Cl ₂ N ₂ O
2g	6-Me	H	5	EtOH	210-212	C ₁₅ H ₁₈ N ₂ O
2h	6-MeO	H	6	EtOH	191-193	C ₁₅ H ₁₈ N ₂ O ₂
2i	7-MeO	H	7	EtOH	192-193	C ₁₅ H ₁₈ N ₂ O ₂
2j	7-n-BuO	H	8	Me ₂ CO	182-184	C ₁₈ H ₂₄ N ₂ O ₂
2k	7-HO	H	9	i-PrOH	245-246	C ₁₄ H ₁₆ N ₂ O ₂
2L	7-EtO	H	10	i-PrOH	184-186	C ₁₆ H ₂₀ N ₂ O ₂
2m	7-n-PrO	H	10	i-PrOH	172-174	C ₁₇ H ₂₂ N ₂ O ₂
2n	7-n-PentO	H	10	i-PrOH	181-182	C ₁₉ H ₂₆ N ₂ O ₂
2o	7-n-HexO	H	10	i-PrOH	177-178	C ₂₀ H ₂₈ N ₂ O ₂
2p	7-PhCH ₂ O	H	10	i-PrOH	187-189	C ₂₁ H ₂₂ N ₂ O ₂

30

35

Table III



5

No.	<u>R₁</u>	<u>R₂</u>	<u>R₃</u>	<u>Example</u>
3a	H	H	H	11
3b	CHO	H	H	12
10 3c	COEt	H	H	13
3d	COBu-n	H	H	13
3e	CO ₂ Et	H	H	13
3f	CO ₂ Me	H	H	13
15 3g	CO ₂ Et	Me	H	14
3h	COMe	Me	H	15
3i	Et	H	H	16
3j	Me	H	H	17
3k	Me	Me	H	17
20 3L	COMe	H	Me	18

	<u>Recrystn Solvent</u>	<u>Mp, °C</u>	<u>Formula</u>
25 3a	aq EtOH	ca. 290 d	C ₁₂ H ₁₄ N ₂ ·HCl
3b	EtOH	169-171	C ₁₃ H ₁₄ N ₂ O
3c	EtOAc	169-170	C ₁₅ H ₁₈ N ₂ O
3d	EtOAc	149-154	C ₁₇ H ₂₂ N ₂ O
3e	EtOH	164-165	C ₁₅ H ₁₈ N ₂ O ₂
3f	MeOH	160-162	C ₁₄ H ₁₆ N ₂ O ₂
30 3g	EtOH	167-168	C ₁₆ H ₂₀ N ₂ O ₂
3h	EtOH	215-216	C ₁₅ H ₁₈ N ₂ O
3i	aq MeOH	263-264	C ₁₄ H ₁₈ N ₂ ·HCl
3j	aq EtOH	252-253	C ₁₃ H ₁₆ N ₂ ·HCl
35 3k	EtOH-i-PrOH	200-201	C ₁₄ H ₁₈ N ₂ ·HCl
3L	EtOAc	171-172	C ₁₅ H ₁₈ N ₂ O

0004342

32

Table IV

Antagonism of Tetrabenazine-Induced Depression
In Mice Orally at 1 Hour Post-Drug

	<u>Compound No.</u>	<u>ED₅₀ (mg/kg) For Prevention of</u>	
		<u>Ptosis</u>	<u>Exploratory Loss</u>
5	1a	0.70	2.3
	1b	2.7	4.2
	1c	3.3	14.0
	1d	2.1	3.3
10	1e	16	34
	1f	27	27
	1g	8.1	15.6
	1h	2.2	4.2
15	1i	8.9	12.7
	1j	0.79	0.99
	1k	0.22	0.35
	1L	2.0	2.0
20	1m	27	27
	1n	6.5	7.2
	1o	3.7	27
	1p	21	21
25	1q	1.7	18
	1r	6.5	7.5
	1s	4.0	4.0
	1t	5.2	9.7
30	1u	0.57	0.75
	1v	2.4	3.0
	1w	68	96
	1x	37	41
35	1y	4.7	5.2
	2a	1.1	2.4

Table IV. (Cbnt'd.


		ED ₅₀ (mg/kg) For Prevention of	
<u>Compound No.</u>		<u>Ptoxis</u>	<u>Exploratory Loss</u>
5	2b	0.70	2.4
	2c	2.4	6.5
	2d	10.0	17.4
	2e	14.0	19.7
	2f	3.3	4.7
10	2g	3.0	7.2
	2h	5.8	6.5
	2i	0.80	0.90
	2j	0.51	0.57
	2k	>125	>125
15	2L	2	2
	2m	0.6	0.6
	2n	2.7	4.3
	2o	14.0	12.0
	2p	6.5	6.5
20	3a	4.0	8.0
	3b	84	>125
	3c	67	>81
	3d	>81	>81
	3e	40	>81
25	3f	>81	>81
	3g	7.8	27
	3h	>125	>125
	3i	27	27
	3j	12	32
30	3k	11.4	39
	3L	9.0	11.2
	35	1.2	2.6
	amitriptyline		

EP-0208


1

CLAIMS

1. A compound of the formula



or



wherein

R_1 is hydrogen, methyl, ethyl, or $R-\overset{\text{O}}{\parallel}{C}-$, where
 R is hydrogen, C_1-C_4 alkyl, methoxy or ethoxy,

R_2 is hydrogen or methyl;

15 R_3 is hydrogen, methyl or ethyl;

Y_1 is hydrogen, fluorine, chlorine, bromine,
hydroxy, methyl, benzyloxy or C_1-C_6 alkoxy;

Y_2 is hydrogen or chlorine;

with the proviso that Y_2 can be chlorine only when Y_1
20 is chlorine;

or its pharmaceutically suitable salt.

2. A compound of Claim 1 further character-
ized by the provision that in Formula II,

R_1 is limited to hydrogen, methyl, ethyl, or

25

$\overset{\text{O}}{\parallel}{C}-$ where R is methyl or ethoxy;

2
 R_2 is hydrogen when R_1 is $R-\overset{\overset{O}{\parallel}}{C}$ and R is methyl;
 Y_1 is limited to hydrogen, fluorine, chlorine, bromine, methyl, benzyloxy or C_1-C_6 alkoxy.

3. The compound of Claim 2 which is cis-N-
 5 (1,3,4,4a,9,9a-hexahydro-2H-carbazol-2-yl)acetamide.

4. The compound of Claim 2 which is cis-N-methyl-2,3,4,4a,9,9a-hexahydro-1H-carbazol-2-amine.


5. The compound of Claim 2 which is ethyl
 (cis-1,3,4,4a,9,9a-hexahydro-2H-carbazol-2-yl) carbamate.

10 6. The compound of Claim 2 which is cis-N-(1,3,4,4a,9,9a-hexahydro-2H-carbazol-2-yl)propanamide.

7. The compound of Claim 2 which is
 N-(1,3,4,9-tetrahydro-2H-carbazol-2-yl)acetamide.

8. A pharmaceutical composition consisting
 15 essentially of a suitable pharmaceutical carrier and a compound of Claim 2.

9. A process for making a compound of the
 formula



wherein

R_1 is hydrogen, methyl, ethyl, or $R-\overset{\overset{O}{\parallel}}{C}-$, where
 25 R is hydrogen, C_1-C_4 alkyl, methoxy or ethoxy;

R_2 is hydrogen or methyl;


R_3 is hydrogen, methyl or ethyl;

Y_1 is hydrogen, fluorine, chlorine, bromine, hydroxy, methyl, benzyloxy or C_1-C_6 alkoxy;

30 Y_2 is hydrogen or chlorine;


with the proviso that Y_2 can be chlorine only when Y_1 is chlorine;

which comprises reducing in an acid medium a compound
 of the formula



3

10. A process for making a compound of the formula



wherein

R_1 is hydrogen, methyl, ethyl, or $R-C(=O)-$, where R is hydrogen, C_1-C_4 alkyl, methoxy or ethoxy;


R_2 is hydrogen or methyl;

R_3 is hydrogen, methyl or ethyl;


Y_1 is hydrogen, fluorine, chlorine, bromine, hydroxy, methyl, benzyloxy or C_1-C_6 alkoxy;

Y_2 is hydrogen or chlorine;

15 which comprises contacting




and



20 in acid medium.

11. A process for making a compound of the formula



wherein

R_1 is hydrogen, methyl, ethyl, or $R-C(=O)-$, where R is hydrogen, C_1-C_4 alkyl, methoxy or ethoxy;

R_2 is hydrogen or methyl;

R_3 is hydrogen, methyl or ethyl;



Y_1 is hydrogen, fluorine, chlorine, bromine, hydroxy, methyl, benzyloxy or C_1-C_6 alkoxy;

Y_2 is hydrogen or chlorine;


35 with the provide that Y_2 can be chlorine only when Y_1 is chlorine;

4

which comprises (A) contacting



in acid medium to obtain a compound of the formula



wherein

R_1 , R_2 , R_3 , Y_1 , and Y_2 are as previously defined,
and (B) reducing in acid medium the compound made in
step (A).

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	<p>CHEMICAL ABSTRACTS, vol. 44, nr. 18 September 25, 1950, column 10155 Columbus, Ohio, U.S.A. E. EAGLE et al.: "Toxicity, anti-pyretic, and analgesic studies on thirty-nine compounds including acetylsalicylic acid, phenacetin, and twenty-seven derivatives of carbazole and tetrahydrocarbazole" & J. PHARMACOL. EXPTL. THERAP. 99, no. 4, Pt. 1, 450-7(1950) * Abstract *</p> <p style="text-align: center;">--</p> <p>CHEMICAL ABSTRACTS, vol. 57, nr. 7 1 October 1962, column 9782 Columbus, Ohio, U.S.A. K.S. MURTHY et al.: "Synthesis of 2-aminocarbazole from 1-morpholinocyclohexene" & J. SCI. IND. RES. 21B, 290-1 (1962) * Abstract *</p> <p style="text-align: center;">----</p>	<p>1-11</p> <p>1-11</p>	<p>C 07 D 209/88 A 61 K 31/40</p> <p>TECHNICAL FIELDS SEARCHED (Int.Cl.)</p> <p>C 07 D 209/88</p> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: conflicting application D: document cited in the application L: citation for other reasons</p> <p>&: member of the same patent family, corresponding document</p>
X	The present search report has been drawn up for all claims		
Place of search	Date of completion of the search	Examiner	
The Hague	22-06-1979	MAISONNEUVE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)